NovoCure Ltd
corporate_fare Company Profile
NovoCure Ltd (NASDAQ:NVCR) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 26 items for NVCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for NVCR spans 8-K, 10-Q, DEFA14A, DEF 14A.
Recent high-impact activity:
- FDA Rejects Optune Mya Brain Metastases PMA With Not Approvable Letter
- NovoCure Beats on Q3 Revenue, Raises 2026 Guidance and Adjusted EBITDA Outlook
- Novocure Narrows Q3 Loss to $10.4M, Turns Adjusted EBITDA Positive and Lifts Full-Year Revenue Outlook
- NovoCure Q3 Revenue Up 16% to $193.4M; Adjusted EBITDA Turns Positive at $15.7M
- Japan Approves Novocure's Optune Pax for Pancreatic Cancer
Financial Snapshot
Short Interest & Short Volume
6.02 days to coverFINRA reported short interest of 12,913,904 shares in NVCR as of the October 30, 2026 settlement, a 0.7% increase from the prior period — about 6.0 days to cover at its recent average daily volume. On November 20, 2026, 59.7% of NVCR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NVCR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
Equity Incentive Plan Approved · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →